@zohmbastic Avatar @zohmbastic zohm

No specific company named "zohm" appears in the provided tweets. However, various companies are trending with updates on earnings, analyst upgrades and downgrades, and new partnerships. Some companies like $MARa, $FIVE, and $RLX reported strong quarterly earnings.

Engagements: [-----] #

Engagements Line Chart

Mentions: [---] #

Mentions Line Chart

Followers: [------] #

Followers Line Chart

CreatorRank: [-------] #

CreatorRank Line Chart

Social Influence

Social category influence stocks 65.79% finance 15.72% cryptocurrencies 8.94% exchanges #4036 technology brands 3.24% financial services #2364 countries 2.31% fashion brands 0.92% vc firms 0.31% currencies 0.31%

Social topic influence target #1875, strong 4.93%, nasdaq #427, company #896, $ua 3.24%, rating #377, in the 2.31%, ai 2.31%, $fsly #59, morgan stanley #65

Top accounts mentioned or mentioned by @doepke_michel @pnani456 @byebyegoodguy @maximusholla @corona_n_lyme @jpvantage25 @sunrgu @trade_velocity @rdglinvestors @monaco_biotech @hellojintao @alexgiovannetti @bussinbiotech @mwm76 @bigchodu @traderbasha

Top assets mentioned Under Armour Inc Class C (UA) Fastly, Inc. (FSLY) Morgan Stanley (MS) Under Armour Inc Class A (UAA) AT&T Inc. (T) Arteris, Inc. (AIP) Goldman Sachs (GS) Erasca, Inc. (ERAS) Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Beta Finance (BETA) Olema Pharmaceuticals, Inc. (OLMA) Kenvue Inc. (KVUE) Cosmos (ATOM) HealthSci.AI (HSAI) Alumis Inc. (ALMS) Verizon Communications Inc. (VZ) Viavi Solutions Inc. Common Stock (VIAV) ACV Auctions Inc. (ACVA) Terns Pharmaceuticals, Inc. (TERN) Devon Energy Corp (DVN) Comcast Corporation (CMCSA) TeraWulf Inc. (WULF) Corsair Gaming, Inc. (CRSR) Unicycive Therapeutics, Inc. (UNCY) BioAge Labs, Inc. (BIOA) AB (prev. Newton) (AB) Landwolf (WOLF) Carnival Corp (CCL) Core Scientific, Inc. Common Stock (CORZ) ALX Oncology Holdings Inc (ALXO) 2131KOBUSHIDE (21) Taysha Gene Therapies, Inc. (TSHA) Immunome, Inc. (IMNM) Applied Optoelectronics, Inc. (AAOI) Brookdale Senior Living, Inc. (BKD) nLIGHT, Inc. Common Stock (LASR) Evommune, Inc. (EVMN) Ramaco Resources, Inc. Common Stock (METC) Roivant Sciences Ltd. Common Shares (ROIV) Fermi Inc. (FRMI) Lumentum Holdings Inc. Common Stock (LITE) Abivax SA (ABVX) Immix Biopharma, Inc. (IMMX) Warby Parker, Inc. (WRBY) Tyra Biosciences, Inc. (TYRA) Venture Global, Inc (VG) Coterra Energy Inc (CTRA) GitLab Inc. (GTLB) Eli Lilly and Company (LLY) Rocket Companies, Inc. (RKT) Super Micro Computer, Inc. Common Stock (SMCI) GoodRx Holdings, Inc. (GDRX) Envista Holdings Corporation Common stock, $0.01 par value per share (NVST) Canton (CC) Arista Networks Inc (ANET) Context Therapeutics Inc. (CNTX) Coupang, Inc. (CPNG) UnitedHealth Group (UNH) Freeport-McMoRan Inc (FCX) COMPASS Pathways plc (CMPS) BETA Technologies, Inc. (BETA) Vertiv Holdings Co (VRT)

Top Social Posts

Top posts by engagements in the last [--] hours

"$FRMI Leading Global Power and Infrastructure Financial Institution MUFG Backs Fermi America with $500 Million Equipment Loan to Accelerate 11GW Private Energy Campus"
X Link 2026-02-10T21:11Z 10.1K followers, [----] engagements

"$BETA Amazon"
X Link 2026-02-10T21:16Z 10.1K followers, 11.4K engagements

"$FRMI $FRMI Leading Global Power and Infrastructure Financial Institution MUFG Backs Fermi America with $500 Million Equipment Loan to Accelerate 11GW Private Energy Campus $FRMI Leading Global Power and Infrastructure Financial Institution MUFG Backs Fermi America with $500 Million Equipment Loan to Accelerate 11GW Private Energy Campus"
X Link 2026-02-13T15:55Z 10.1K followers, [----] engagements

"$VTGN update The Company expects topline results for the randomized portion of its ongoing PALISADE-4 Phase [--] trial of fasedienol for the acute treatment of social anxiety disorder in the first half of 2026"
X Link 2026-02-12T21:32Z 10.1K followers, [----] engagements

"$GPUS $GPUS on the way to be the best company in the world Milton lol $GPUS on the way to be the best company in the world Milton lol"
X Link 2026-02-13T21:34Z 10.1K followers, [----] engagements

"$CPNG if 17.5ish cracks may had to [--] @pnani456 $CPNG lobbysts work maybe Clown activated. @pnani456 $CPNG lobbysts work maybe Clown activated"
X Link 2026-02-05T15:35Z 10.1K followers, [----] engagements

"$LPTH $LPTH Canaccord [----] from [--] HCW [--] from [--] Canaccord analyst Austin Moeller raised the firm's price target on LightPath to $15.50 from $15 and keeps a Buy rating on the shares. The firm noted they posted a top and bottom line beat as its strong demand signals suggest growth is $LPTH Canaccord [----] from [--] HCW [--] from [--] Canaccord analyst Austin Moeller raised the firm's price target on LightPath to $15.50 from $15 and keeps a Buy rating on the shares. The firm noted they posted a top and bottom line beat as its strong demand signals suggest growth is"
X Link 2026-02-12T15:24Z 10.1K followers, [---] engagements

"Soros fund management a few new notable positions: $KVUE $DBRG $CLFT $FOLD $CRWV etc increased $CYBR $MSFT $UBER $DASH $LION $NVDA $UNH $AAPL $EVGO $CRM etc"
X Link 2026-02-13T21:52Z 10.1K followers, [----] engagements

"$ABSI https://www.sec.gov/Archives/edgar/data/1672688/000167268825000096/xslF345X05/wk-form4_1765314257.xml https://www.sec.gov/Archives/edgar/data/1672688/000167268825000096/xslF345X05/wk-form4_1765314257.xml"
X Link 2025-12-09T21:06Z 10.1K followers, [----] engagements

"$OVID Point72 13G 6.7M 5.1% $OVID https://t.co/niZF8wEZT6 $OVID https://t.co/niZF8wEZT6"
X Link 2026-01-05T21:14Z 10.1K followers, 11.8K engagements

"$FCX UBS analyst Daniel Major raised the firm's price target on Freeport-McMoRan to $70 from $60 and keeps a Buy rating on the shares. $FCX https://t.co/62aqdhLmAp $FCX https://t.co/62aqdhLmAp"
X Link 2026-01-23T12:58Z 10.1K followers, [----] engagements

"$CMPS RBC Capital analyst Leonid Timashev raised the firm's price target on Compass Pathways to $21 from $16 and keeps an Outperform rating on the shares. Following the firm's Psychedelics Symposium the firm is introducing a few changes to its CMPS model to better reflect the attitudes of key opinion leaders and companies on pricing as well as the barriers to generic entry in the emerging innovative psychedelic therapy landscape the analyst tells investors in a research note. $CMPS https://t.co/8oCACgw4tS $CMPS https://t.co/8oCACgw4tS"
X Link 2026-01-23T19:27Z 10.1K followers, [----] engagements

"$MIST Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)"
X Link 2026-01-26T13:04Z 10.1K followers, [---] engagements

"$VIAV not bad $VIAV impressive holding power https://t.co/j7eQyRQaCs $VIAV impressive holding power https://t.co/j7eQyRQaCs"
X Link 2026-02-02T14:47Z 10.1K followers, [----] engagements

"$VIAV [--] holla $VIAV pcr .07 so far today https://t.co/ezdu3RTdEf $VIAV pcr .07 so far today https://t.co/ezdu3RTdEf"
X Link 2026-02-05T16:40Z 10.1K followers, [----] engagements

"$VIAV $VIAV [--] holla $VIAV [--] holla"
X Link 2026-02-06T19:08Z 10.1K followers, [----] engagements

"$LITE nearing [---] $LITE [---] $LITE 550"
X Link 2026-02-09T14:54Z 10.1K followers, [----] engagements

"$VIAV [--] pcr .049 today $VIAV https://t.co/ld8oZIw2wD $VIAV https://t.co/ld8oZIw2wD"
X Link 2026-02-09T16:11Z 10.1K followers, [----] engagements

"$BETA (Beta Technologies Inc) some folks hit $BBNX (Beta Bionics) lol $BETA Amazon https://t.co/hRsCoja4RU $BETA Amazon https://t.co/hRsCoja4RU"
X Link 2026-02-10T21:22Z 10.1K followers, [----] engagements

"$VRT Vertiv Holdings Sees Q1 Adj EPS $0.95-$1.01 vs $0.94 Est; Sees Sales $2.500B-$2.700B vs $2.528B Est Vertiv Holdings Sees Q1 Adj EPS $0.95-$1.01 vs $0.94 Est; Sees Sales $2.500B-$2.700B vs $2.528B Est Vertiv Holdings Sees FY2026 Adj EPS $5.97-$6.07 vs $5.33 Est; Sees Sales $13.250B-$13.750B vs $12.388B Est $VRT hit all time high today https://t.co/mHG1URr146 $VRT hit all time high today https://t.co/mHG1URr146"
X Link 2026-02-11T12:35Z 10.1K followers, [----] engagements

"$BTU TRUMP: WILL BUY A LOT OF COAL THROUGH THE U.S. MILITARY TRUMP: WILL BUY A LOT OF COAL THROUGH THE U.S. MILITARY"
X Link 2026-02-11T21:48Z 10.1K followers, [----] engagements

"$LPTH $LPTH Canaccord [----] from [--] HCW [--] from [--] Canaccord analyst Austin Moeller raised the firm's price target on LightPath to $15.50 from $15 and keeps a Buy rating on the shares. The firm noted they posted a top and bottom line beat as its strong demand signals suggest growth is $LPTH Canaccord [----] from [--] HCW [--] from [--] Canaccord analyst Austin Moeller raised the firm's price target on LightPath to $15.50 from $15 and keeps a Buy rating on the shares. The firm noted they posted a top and bottom line beat as its strong demand signals suggest growth is"
X Link 2026-02-12T15:17Z 10.1K followers, [---] engagements

"$PTCT PTC Therapeutics Inc. (NASDAQ: PTCT)announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) following U.S. Food and Drug Administration (FDA) feedback on the application review. "FDA shared that based on its review to date the data in the NDA submission are unlikely to meet the Agency's threshold of substantial evidence of effectiveness to support approval of Translarna. We have therefore made the decision to withdraw the NDA submission"said Matthew B. Klein M.D."
X Link 2026-02-12T22:01Z 10.1K followers, [----] engagements

"$FCX Argus analyst Alexandra Yates upgraded Freeport-McMoRan to Buy from Hold. $FCX UBS analyst Daniel Major raised the firm's price target on Freeport-McMoRan to $70 from $60 and keeps a Buy rating on the shares. $FCX UBS analyst Daniel Major raised the firm's price target on Freeport-McMoRan to $70 from $60 and keeps a Buy rating on the shares"
X Link 2026-02-13T12:30Z 10.1K followers, [----] engagements

"$CTMX Barclays raised the firm's price target on CytomX Therapeutics to $10 from $8 and keeps an Overweight rating on the shares as part of a Q4 earnings preview for the biotechnology group. $CTMX continuation https://t.co/TIu8ho8kk9 $CTMX continuation https://t.co/TIu8ho8kk9"
X Link 2026-02-13T15:31Z 10.1K followers, [----] engagements

"$NKTR some 70c hit then some 60p sellers $NKTR [--] $NKTR 70"
X Link 2026-02-13T17:44Z 10.1K followers, [----] engagements

"$ABVX Vivo $ABVX https://t.co/BWYdSv0hPI $ABVX https://t.co/BWYdSv0hPI"
X Link 2026-02-13T19:33Z 10.1K followers, [----] engagements

"$ATOM [--] / [----] potential from here $ATOM maybe mid 3.8s / [--] big zone $ATOM maybe mid 3.8s / [--] big zone"
X Link 2026-02-13T20:19Z 10.1K followers, [----] engagements

"$IRDM decent action"
X Link 2026-02-12T15:29Z 10.1K followers, [----] engagements

"$ABVX Frazier $ABVX Vivo https://t.co/vPsSRxddcO $ABVX Vivo https://t.co/vPsSRxddcO"
X Link 2026-02-13T19:58Z 10.1K followers, [----] engagements

"$GPUS on the way to be the best company in the world Milton lol"
X Link 2026-02-13T21:31Z 10.1K followers, [----] engagements

"$LVRO Lavoro Announces Voluntary Delisting from the Nasdaq Global Market"
X Link 2026-02-13T22:04Z 10.1K followers, [----] engagements

"$IMRX Immuneering Corporation (Nasdaq: IMRX) a clinical-stage oncology company focused on keeping cancer patients alive today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor olomorasib (LY3537982). The supply agreement supports the evaluation of Immuneerings lead product candidate atebimetinib (IMM-1-104) a novel dual MEK inhibitor in combination with olomorasib in a planned Phase [--] clinical trial in patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on"
X Link 2025-08-25T12:00Z 10.1K followers, [----] engagements

"$NKTX 2H catalyst Ra #1 holder cash 3.19/sh fwiw $NKTX [---] key https://t.co/UhpjNx8l34 $NKTX [---] key https://t.co/UhpjNx8l34"
X Link 2025-10-15T18:06Z 10.1K followers, [----] engagements

"$TSHA looks like more upside can come RJ pt [--] Raymond James initiated coverage of Taysha Gene Therapies with a Strong Buy rating and $13 price target. Based on "strong results" from Part A of the Phase 1/2 REVEAL trial and "constructive" feedback from FDA the firm views Taysha as well-positioned for success in its pivotal trial for patients with Rett syndrome the analyst tells investors. There are currently no approved therapies addressing the root genetic cause of Rett syndrome which the firm sees giving Taysha "a clear path to success" the analyst added. $TSHA Previously disclosed 100%"
X Link 2025-10-20T20:19Z 10.1K followers, [----] engagements

"$SNDK SanDisk Q1 Adj. EPS $1.22 Beats $1.00 Estimate Sales $2.308B Beat $2.164B Estimate / SanDisk Sees Q2 Adj EPS $3.00-$3.40 vs $1.75 Est; Sees Sales $2.550B-$2.650B vs $2.342B Est $SNDK Nov 225c sweep $SNDK Nov 225c sweep"
X Link 2025-11-06T21:13Z 10.1K followers, [----] engagements

"$ACVA https://www.sec.gov/Archives/edgar/data/1252022/000119312525278383/xslF345X05/ownership.xml https://www.sec.gov/Archives/edgar/data/1252022/000119312525278383/xslF345X05/ownership.xml"
X Link 2025-11-13T18:13Z 10.1K followers, [----] engagements

"$acva https://www.sec.gov/Archives/edgar/data/1637873/000185160525000003/0001851605-25-000003-index.htm $ACVA https://t.co/IiAAqISCDu https://t.co/FPB4S17mTW https://www.sec.gov/Archives/edgar/data/1637873/000185160525000003/0001851605-25-000003-index.htm $ACVA https://t.co/IiAAqISCDu https://t.co/FPB4S17mTW"
X Link 2025-11-14T22:50Z 10.1K followers, [----] engagements

"$ACVA more https://www.sec.gov/Archives/edgar/data/1637873/000180880625000003/xslF345X05/wk-form4_1763500606.xml $acva https://t.co/3vDMjoK0Ja https://www.sec.gov/Archives/edgar/data/1637873/000180880625000003/xslF345X05/wk-form4_1763500606.xml $acva https://t.co/3vDMjoK0Ja"
X Link 2025-11-18T21:18Z 10.1K followers, [----] engagements

"$SG $SG hit 6.6s today https://t.co/thizNVnCeB $SG hit 6.6s today https://t.co/thizNVnCeB"
X Link 2025-11-21T20:25Z 10.1K followers, [----] engagements

"$CGEM that 15c up quite a bit $CGEM https://t.co/JQmrVZwzlv $CGEM https://t.co/JQmrVZwzlv"
X Link 2025-11-24T19:28Z 10.1K followers, [----] engagements

"$ACVA locked a few 7.4s $ACVA [--] https://t.co/rY0Dx34RPe $ACVA [--] https://t.co/rY0Dx34RPe"
X Link 2025-11-25T15:02Z 10.1K followers, [----] engagements

"$ACVA decent vol pop $ACVA locked a few 7.4s https://t.co/5c8Ugz4OaE $ACVA locked a few 7.4s https://t.co/5c8Ugz4OaE"
X Link 2025-11-26T20:46Z 10.1K followers, [----] engagements

"$MLCO $MLCO ww especially after regular session open Casino sector doing well has presence in Asia quite positive looking ER # across Macau Cyprus Philliphines region. Melco Resorts and Enter Q3 Adj. EPS $0.21 Beats $0.12 Estimate Sales $1.309B Beat $1.282B Estimate $MLCO ww especially after regular session open Casino sector doing well has presence in Asia quite positive looking ER # across Macau Cyprus Philliphines region. Melco Resorts and Enter Q3 Adj. EPS $0.21 Beats $0.12 Estimate Sales $1.309B Beat $1.282B Estimate"
X Link 2025-12-01T14:45Z 10.1K followers, [----] engagements

"$ACVA nearing [--] $ACVA decent vol pop $ACVA decent vol pop"
X Link 2025-12-01T14:57Z 10.1K followers, [----] engagements

"$AIP weekly $AIP https://t.co/bTWlyaHeBu $AIP https://t.co/bTWlyaHeBu"
X Link 2025-12-02T15:09Z 10.1K followers, [----] engagements

"$AIP $AIP weekly https://t.co/gxYk4kkFus $AIP weekly https://t.co/gxYk4kkFus"
X Link 2025-12-03T18:43Z 10.1K followers, [----] engagements

"$adma finally 20s $ADMA weekly prob [--] break setup soon https://t.co/ybtvAsNnJN $ADMA weekly prob [--] break setup soon https://t.co/ybtvAsNnJN"
X Link 2025-12-03T19:15Z 10.1K followers, [----] engagements

"$BLND $BLND vs 3-3.05 zone https://t.co/4kRtBl0413 $BLND vs 3-3.05 zone https://t.co/4kRtBl0413"
X Link 2025-12-04T14:51Z 10.1K followers, [----] engagements

"$TSHA back to [--] $TSHA daily bnce https://t.co/pUxpRopCzS $TSHA daily bnce https://t.co/pUxpRopCzS"
X Link 2025-12-04T15:42Z 10.1K followers, [----] engagements

"$AIP $AIP https://t.co/I1DrZX4jTD $AIP https://t.co/I1DrZX4jTD"
X Link 2025-12-04T17:05Z 10.1K followers, [----] engagements

"$BMEA BMEA Biomea Fusion Reports Durable Glycemic And C-Peptide Improvements [--] Months After Last Dose In COVALENT-111 With Icovamenib $BMEA https://t.co/AJjw0UObjO $BMEA https://t.co/AJjw0UObjO"
X Link 2025-12-05T13:29Z 10.1K followers, [----] engagements

"$AIP 17.2ish key being tested $AIP https://t.co/eOYp4n9jIC $AIP https://t.co/eOYp4n9jIC"
X Link 2025-12-05T16:36Z 10.1K followers, [----] engagements

"$AIP $AIP 17.2ish key being tested $AIP 17.2ish key being tested"
X Link 2025-12-05T17:58Z 10.1K followers, [----] engagements

"$OCUL H.C. Wainwright raised the firm's price target on Ocular Therapeutix to $21 from $19 and keeps a Buy rating on the shares. RBC RAISES TARGET PRICE TO $30 FROM $24"
X Link 2025-12-08T12:45Z 10.1K followers, [----] engagements

"$TSHA weekly $TSHA back to [--] https://t.co/7YFgBGVjXd $TSHA back to [--] https://t.co/7YFgBGVjXd"
X Link 2025-12-08T19:36Z 10.1K followers, [----] engagements

"$SG decent come back one of sqz candidates $SG https://t.co/AzwIKkDENB $SG https://t.co/AzwIKkDENB"
X Link 2025-12-09T18:06Z 10.1K followers, [----] engagements

"$BLND $BLND vs 3-3.05 zone https://t.co/4kRtBl0413 $BLND vs 3-3.05 zone https://t.co/4kRtBl0413"
X Link 2025-12-09T19:30Z 10.1K followers, [----] engagements

"$CMPS Oppenheimer upgraded Compass Pathways to Outperform from Perform with a $15 price target"
X Link 2025-12-09T21:10Z 10.1K followers, [----] engagements

"$IMMX Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Financing includes leading U.S. biotechnology institutional investors and mutual funds Morgan Stanley was a book-running manager $IMMX near [--] $IMMX near 7"
X Link 2025-12-10T00:24Z 10.1K followers, [----] engagements

"$IMMX $3 run ever since daily break $IMMX https://t.co/w4RggMrHYA $IMMX https://t.co/w4RggMrHYA"
X Link 2025-12-10T15:28Z 10.1K followers, [----] engagements

"$TSHA $TSHA weekly https://t.co/nZVKYbxdEN $TSHA weekly https://t.co/nZVKYbxdEN"
X Link 2025-12-10T20:44Z 10.1K followers, [----] engagements

"$GEMI 14s $GEMI pcr .164 https://t.co/lpg5vHeXQD $GEMI pcr .164 https://t.co/lpg5vHeXQD"
X Link 2025-12-11T18:22Z 10.1K followers, [----] engagements

"$IMMX now well above IPO price $5 $IMMX director Nancy Chang holds 422k shs directly and total about 500k shs. Awarded stock 40k options with [----] exercise price vesting in [--] months Chang was Tanox founder which later acquired by Genetech back in [----] https://www.sec.gov/Archives/edgar/data/1135041/000149315225027329/xslF345X05/ownership.xml $IMMX $3 run ever since daily break https://t.co/sMMLtI9zVh https://www.sec.gov/Archives/edgar/data/1135041/000149315225027329/xslF345X05/ownership.xml $IMMX $3 run ever since daily break https://t.co/sMMLtI9zVh"
X Link 2025-12-12T15:22Z 10.1K followers, [----] engagements

"$OLMA $OLMA Citi raised the firm's price target on Olema Oncology (OLMA) to $60 from $21 and keeps a Buy rating on the shares. Citi also added an "upside 90-day catalyst watch" on Olema. The firm says Roche's (RHHBY) positive Phase [--] lidERA trial data shows the "practice changing" $OLMA Citi raised the firm's price target on Olema Oncology (OLMA) to $60 from $21 and keeps a Buy rating on the shares. Citi also added an "upside 90-day catalyst watch" on Olema. The firm says Roche's (RHHBY) positive Phase [--] lidERA trial data shows the "practice changing""
X Link 2025-12-15T15:02Z 10.1K followers, [----] engagements

"$INAB PIPE priced [----] $20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619 IN8bios novel gamma-delta () T cell engager through an Investigational New Drug (IND) application Financing led by Coastlands Capital with participation from new and existing biotechnology investors Initial proceeds extend cash runway into the first half of [----] https://twitter.com/i/web/status/2002001384120426789 https://twitter.com/i/web/status/2002001384120426789"
X Link 2025-12-19T13:01Z 10.1K followers, [----] engagements

"$VERA Goldman Sachs [--] from [--] JPMorgan [--] from [--] BofA [--] from [--] Goldman Sachs raised the firm's price target on Vera Therapeutics to $95 from $55 and keeps a Buy rating on the shares. Following FDA approval and unexpectedly high pricing of Otsuka's Voyxact assumptions for Vera were revised to reflect a meaningfully larger TAM and higher pricing potential for the APRIL/BAFF inhibitor class in IgAN the analyst tells investors in a research note. https://twitter.com/i/web/status/2002060985763271078 https://twitter.com/i/web/status/2002060985763271078"
X Link 2025-12-19T16:58Z 10.1K followers, [----] engagements

"$GAP $GAP nearing [--] $GAP nearing 28"
X Link 2025-12-19T20:11Z 10.1K followers, [----] engagements

"$VERA $VERA Goldman Sachs [--] from [--] JPMorgan [--] from [--] BofA [--] from [--] Goldman Sachs raised the firm's price target on Vera Therapeutics to $95 from $55 and keeps a Buy rating on the shares. Following FDA approval and unexpectedly high pricing of Otsuka's Voyxact assumptions for $VERA Goldman Sachs [--] from [--] JPMorgan [--] from [--] BofA [--] from [--] Goldman Sachs raised the firm's price target on Vera Therapeutics to $95 from $55 and keeps a Buy rating on the shares. Following FDA approval and unexpectedly high pricing of Otsuka's Voyxact assumptions for"
X Link 2025-12-19T20:46Z 10.1K followers, [----] engagements

"$AIP daily bnce $AIP Arteris Inc. (Nasdaq: AIP) a leading provider of system IP for accelerating semiconductor creation in the AI era today announced it has entered into a definitive agreement to acquire Cycuity Inc. a leading provider of semiconductor cybersecurity assurance. The addition $AIP Arteris Inc. (Nasdaq: AIP) a leading provider of system IP for accelerating semiconductor creation in the AI era today announced it has entered into a definitive agreement to acquire Cycuity Inc. a leading provider of semiconductor cybersecurity assurance. The addition"
X Link 2025-12-22T18:03Z 10.1K followers, [----] engagements

"$IMNM $IMNM from offer https://t.co/qKG6Zfa710 $IMNM from offer https://t.co/qKG6Zfa710"
X Link 2025-12-22T18:23Z 10.1K followers, [----] engagements

"$TCRX https://www.sec.gov/Archives/edgar/data/1783328/000090266425005396/xslF345X03/ownership.xml https://www.sec.gov/Archives/edgar/data/1783328/000090266425005396/xslF345X03/ownership.xml"
X Link 2025-12-24T14:07Z 10.1K followers, [----] engagements

"$OMER Jan 10c largest $vol Jan 15c highest OI Jan 20c largest vol $OMER H.C. Wainwright reiterated a Buy rating and $20 price target on Omeros following the FDA approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The firm sees the Yartemlea approval as a "significant validation" of Omeros value. $OMER H.C. Wainwright reiterated a Buy rating and $20 price target on Omeros following the FDA approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The firm sees the Yartemlea approval as a "significant"
X Link 2025-12-24T16:28Z 10.1K followers, [----] engagements

"$INAB $INAB PIPE priced [----] $20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619 IN8bios novel gamma-delta () T cell engager through an Investigational New Drug (IND) application Financing led by Coastlands Capital with participation from $INAB PIPE priced [----] $20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619 IN8bios novel gamma-delta () T cell engager through an Investigational New Drug (IND) application Financing led by Coastlands Capital with participation from"
X Link 2025-12-24T17:23Z 10.1K followers, [----] engagements

"$TCRX $TCRX https://t.co/Pd2aJfvl2L $TCRX https://t.co/Pd2aJfvl2L"
X Link 2025-12-26T19:02Z 10.1K followers, [----] engagements

"$TSHA Wells Fargo analyst Zachary Fadem raised the firm's price target on Taysha Gene Therapies to $11 from $8 and keeps an Overweight rating on the shares. The firm sees another year of outperformance for the stock driven by continued momentum in the company's pivotal Rett syndrome study following last year's alignment with FDA on a favorable design. $TSHA looks like more upside can come RJ pt [--] Raymond James initiated coverage of Taysha Gene Therapies with a Strong Buy rating and $13 price target. Based on "strong results" from Part A of the Phase 1/2 REVEAL trial and "constructive""
X Link 2026-01-05T13:27Z 10.1K followers, [----] engagements

"$OSCR Barclays analyst Andrew Mok upgraded Oscar Health to Equal Weight from Underweight with a price target of $18 up from $13. The firm sees managed care stocks benefiting in [----] from the prospects of margin expansion and rotation away from artificial intelligence-related stocks toward "de-rated underperformers." Oscar is priced attractively as the market is currently over-discounting the negative outcomes from expiring subsidies the analyst tells investors in a research note. https://twitter.com/i/web/status/2008170881537671659 https://twitter.com/i/web/status/2008170881537671659"
X Link 2026-01-05T13:37Z 10.1K followers, [----] engagements

"$HSAI lidar name in china"
X Link 2026-01-06T15:05Z 10.1K followers, [----] engagements

"$HSAI near [--] $HSAI lidar name in china https://t.co/N0q96XW6s2 $HSAI lidar name in china https://t.co/N0q96XW6s2"
X Link 2026-01-06T17:14Z 10.1K followers, [----] engagements

"$AIP $AIP daily bnce https://t.co/sAeKyHphDo $AIP daily bnce https://t.co/sAeKyHphDo"
X Link 2026-01-06T20:05Z 10.1K followers, [----] engagements

"$OLMA Piper Sandler initiated coverage of Olema Oncology with an Overweight rating and $40 price target. The firm believes the company's palazestrant can become the next "backbone" endocrine therapy in the large ER+/HER2- breast cancer market. $OLMA Citi raised the firm's price target on Olema Oncology (OLMA) to $60 from $21 and keeps a Buy rating on the shares. Citi also added an "upside 90-day catalyst watch" on Olema. The firm says Roche's (RHHBY) positive Phase [--] lidERA trial data shows the "practice changing" $OLMA Citi raised the firm's price target on Olema Oncology (OLMA) to $60 from"
X Link 2026-01-07T13:15Z 10.1K followers, [----] engagements

"$HSAI pcr .223 for now $HSAI near [--] $HSAI near 27"
X Link 2026-01-07T18:21Z 10.1K followers, [----] engagements

"$OLMA daily curl $OLMA Piper Sandler initiated coverage of Olema Oncology with an Overweight rating and $40 price target. The firm believes the company's palazestrant can become the next "backbone" endocrine therapy in the large ER+/HER2- breast cancer market. $OLMA Piper Sandler initiated coverage of Olema Oncology with an Overweight rating and $40 price target. The firm believes the company's palazestrant can become the next "backbone" endocrine therapy in the large ER+/HER2- breast cancer market"
X Link 2026-01-07T20:46Z 10.1K followers, [----] engagements

"$COST COSTCO WHOLESALE CORPORATION REPORTS DECEMBER SALES RESULTS COSTCO WHOLESALE CORP - REPORTS DECEMBER NET SALES OF $29.86 BLN COSTCO WHOLESALE CORP - DECEMBER COMPARABLE SALES U.S. 6.0% CANADA 8.4% OTHER INTERNATIONAL 10.6%"
X Link 2026-01-07T21:17Z 10.1K followers, [----] engagements

"$VTYX Under the terms of the agreement Lilly will acquire all of the outstanding shares of Ventyx for $14.00 per share of common stock in an all-cash transaction (equal to an aggregate equity value of approximately $1.2 billion). The transaction is not subject to any financing condition and is expected to close in the first half of [----] subject to approval by Ventyx stockholders and satisfaction of other customary closing conditions including regulatory approvals. $VTYX overnight session hit 19s VTYX UBS initiated coverage of Ventyx Biosciences with a Buy rating and $20 price target as the"
X Link 2026-01-07T21:19Z 10.1K followers, 17.2K engagements

"$VTYX time to say goodbye $VTYX Under the terms of the agreement Lilly will acquire all of the outstanding shares of Ventyx for $14.00 per share of common stock in an all-cash transaction (equal to an aggregate equity value of approximately $1.2 billion). The transaction is not subject to any financing $VTYX Under the terms of the agreement Lilly will acquire all of the outstanding shares of Ventyx for $14.00 per share of common stock in an all-cash transaction (equal to an aggregate equity value of approximately $1.2 billion). The transaction is not subject to any financing"
X Link 2026-01-07T21:20Z 10.1K followers, [----] engagements

"$SKYX NVIDIA Connect Supports Advanced Technology Companies Developing AI-powered Products Part of NVIDIAs Connect Program is to Promote Assist and Identify Go-To-Market Opportunities SKYX Expects to Include its All-In-One Smart Platform and Hub in Collaboration with NVIDIAs AI Features in Future U.S. and Global Projects Including the Upcoming $4 Billion Miami Florida Smart City NVIDIA Connect is Designed to Help Build AI Solutions Faster Accelerate Growth and Maximize Opportunities while Delivering a Range of Significant AI Ecosystem Advantages as Well as Free Benefits SKYXs Technologies"
X Link 2026-01-08T13:12Z 10.1K followers, [----] engagements

"$HSAI decent intra flow $HSAI pcr .223 for now https://t.co/6OOp598kVR $HSAI pcr .223 for now https://t.co/6OOp598kVR"
X Link 2026-01-08T15:22Z 10.1K followers, [----] engagements

"$GAP $GAP https://t.co/1yz1xvaMLs $GAP https://t.co/1yz1xvaMLs"
X Link 2026-01-08T16:23Z 10.1K followers, [----] engagements

"$CZR $CZR some Jan spread trades pcr .168 https://t.co/zTtZ9rkNf6 $CZR some Jan spread trades pcr .168 https://t.co/zTtZ9rkNf6"
X Link 2026-01-08T17:45Z 10.1K followers, [----] engagements

"great gap ups on nuclear name $OKLO Oklo And Meta Announce Agreement To Support Development Of A [---] GW Advanced Nuclear Power Campus In Southern Ohio For Meta Data Centers $VST $VSTL $SMR $NNE $IMSR $NKLR reactor names gapping up - $OKLO $SMR $NNE $NKLR $IMSR reactor names gapping up - $OKLO $SMR $NNE $NKLR $IMSR"
X Link 2026-01-09T13:48Z 10.1K followers, [----] engagements

"$TCRX $TCRX https://t.co/Pd2aJfvl2L $TCRX https://t.co/Pd2aJfvl2L"
X Link 2026-01-09T19:15Z 10.1K followers, [----] engagements

"$OLMA back to [--] $OLMA daily curl https://t.co/kWflBZEFDq $OLMA daily curl https://t.co/kWflBZEFDq"
X Link 2026-01-09T20:46Z 10.1K followers, [----] engagements

"$ALMS closed upsized offering Alumis Inc. (Nasdaq: ALMS) a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases today announced the closing of its upsized underwritten public offering of [--------] shares of its common stock including the full exercise of the underwriters' option to purchase an additional [-------] shares at a price to the public of $17.00 per share. The gross proceeds to Alumis from the offering before deducting underwriting discounts and commissions and offering expenses were approximately $345.1"
X Link 2026-01-09T21:05Z 10.1K followers, 15.5K engagements

"$GDS $gds trim order went thru 40.7s $gds trim order went thru 40.7s"
X Link 2026-01-12T14:56Z 10.1K followers, [----] engagements

"$SNPS so far so good $SNPS $NVDA NVIDIA and Synopsys Announce Strategic Partnership to Revolutionize Engineering and Design $SNPS $NVDA NVIDIA and Synopsys Announce Strategic Partnership to Revolutionize Engineering and Design"
X Link 2026-01-12T16:27Z 10.1K followers, [----] engagements

"$OLMA $OLMA back to [--] https://t.co/0Tg4BbV1Rp $OLMA back to [--] https://t.co/0Tg4BbV1Rp"
X Link 2026-01-12T17:01Z 10.1K followers, [----] engagements

"$NKLR decent intra block $NKLR former $GSRT nuclear sector rotation BRiley had $10 PT https://t.co/4nftGPELy7 $NKLR former $GSRT nuclear sector rotation BRiley had $10 PT https://t.co/4nftGPELy7"
X Link 2026-01-12T18:25Z 10.1K followers, [----] engagements

"$BILI had 31c on china strength decent so far $BILI https://t.co/CqBLhBM02r $BILI https://t.co/CqBLhBM02r"
X Link 2026-01-12T19:41Z 10.1K followers, [----] engagements

"$FRMI Feb 10c 20c spread"
X Link 2026-01-12T20:24Z 10.1K followers, [----] engagements

"$RVMD After Revolution Medicines (RVMD) presented pipeline updates and its [----] outlook at a competitor conference in the wake of a report that Merck (MRK) is in talks to acquire Revolution for $28B-$32B Stifel analyst Laura Prendergast said the updates "have us thinking that this speculated $28-32B range might not be enough." As a company policy Revolution does not comment on rumors or speculation notes the analyst whose target price and Buy rating are currently under review as the firm further evaluates the impact of this Revolution M&A speculation and today's updates. $RVMD"
X Link 2026-01-12T20:28Z 10K followers, [----] engagements

"$WAY Citi notes Waystar's (WAY) stock is down about 6% today which the firm attributes to Anthropic's expansion of its Healthcare AI tools and in particular the company further encroaching on the RCM space. However the firm thinks Waystar has been front-footed in developing its own AI tools with Google (GOOGL) and argues that its scale centralized and curated data and domain expertise is "a significant moat that will be difficult for big tech to replicate." Citi has a Buy rating and $46 price target on Waystar shares https://twitter.com/i/web/status/2010820077445169199"
X Link 2026-01-12T21:04Z 10.1K followers, [----] engagements

"$WRBY $WRBY https://t.co/7NaJL72NaJ $WRBY https://t.co/7NaJL72NaJ"
X Link 2026-01-13T14:46Z 10.1K followers, [----] engagements

"$WRBY $WRBY https://t.co/0Y7ppI30cj $WRBY https://t.co/0Y7ppI30cj"
X Link 2026-01-13T15:01Z 10.1K followers, [----] engagements

"$WRBY 30-31 should be key zone $WRBY https://t.co/oe9cP6M51b $WRBY https://t.co/oe9cP6M51b"
X Link 2026-01-13T15:08Z 10.1K followers, [----] engagements

"$ANNX $ANNX daily decent come back https://t.co/ktqSDlKSdc $ANNX daily decent come back https://t.co/ktqSDlKSdc"
X Link 2026-01-13T18:57Z 10.1K followers, [----] engagements

"$VTRS lazy river"
X Link 2026-01-13T20:14Z 10.1K followers, [---] engagements

"$IMRX insider https://www.sec.gov/Archives/edgar/data/1790340/000179034026000008/xslF345X05/wk-form4_1768396231.xml https://www.sec.gov/Archives/edgar/data/1790340/000179034026000008/xslF345X05/wk-form4_1768396231.xml"
X Link 2026-01-14T13:36Z 10.1K followers, [----] engagements

"$WRBY $WRBY 30-31 should be key zone $WRBY 30-31 should be key zone"
X Link 2026-01-14T15:13Z 10.1K followers, [----] engagements

"$UNCY $UNCY https://t.co/P4nRI6pCQH $UNCY https://t.co/P4nRI6pCQH"
X Link 2026-01-14T15:26Z 10.1K followers, [----] engagements

"$UNCY intra high $UNCY https://t.co/XvKp8MRUJe $UNCY https://t.co/XvKp8MRUJe"
X Link 2026-01-14T17:59Z 10.1K followers, [----] engagements

"$TERN daily $TERN daily bnce https://t.co/ahF1ooTg2B $TERN daily bnce https://t.co/ahF1ooTg2B"
X Link 2026-01-14T18:02Z 10.1K followers, [----] engagements

"$UAA $UA $UA $UAA another good day https://t.co/8vzkSVkiMd $UA $UAA another good day https://t.co/8vzkSVkiMd"
X Link 2026-01-14T19:22Z 10.1K followers, [----] engagements

"$ALHC [--] holla $ALHC UBS raised the firm's price target on Alignment Healthcare to $21 from $18 and keeps a Neutral rating on the shares. $ALHC UBS raised the firm's price target on Alignment Healthcare to $21 from $18 and keeps a Neutral rating on the shares"
X Link 2026-01-14T19:37Z 10.1K followers, [----] engagements

"$BIOA not slow anymore 😅 $BIOA slow and steady https://t.co/SBaAHTgf1X $BIOA slow and steady https://t.co/SBaAHTgf1X"
X Link 2026-01-14T20:14Z 10.1K followers, [----] engagements

"$ANNX $ANNX https://t.co/5nv1prcSGP $ANNX https://t.co/5nv1prcSGP"
X Link 2026-01-14T20:19Z 10.1K followers, [----] engagements

"$AIP Arteris Inc. (Nasdaq: AIP) a leading technology provider for accelerating semiconductor creation in the AI era today announced it has closed its previously announced acquisition of Cycuity Inc. a leading provider and domain expert of semiconductor cybersecurity assurance technology. Semiconductor cybersecurity assurance is becoming critical to all types of chip designs as the threat landscape has expanded to the hardware layer. Silicon vulnerabilities can result in compromised systems exposing unprotected information a trend accelerated by the proliferation of AI and chiplets. Reported"
X Link 2026-01-14T21:06Z 10.1K followers, [----] engagements

"$ZETA Morgan Stanley raised the firm's price target on Zeta Global to $27 from $23. Application SaaS names underperformed both the broader software group and the technology sector in [----] but evidence is building that AI-related risks may prove less severe than initially feared supporting a more constructive outlook for application SaaS in [----] the analyst tells investors in a look-ahead note for the group. However a continued lack of broad-based positive spending revisions keeps the firm "selectively opportunistic" the analyst added. $ZETA https://t.co/tPjd2WQ814 $ZETA https://t.co/tPjd2WQ814"
X Link 2026-01-15T12:40Z 10.1K followers, 11K engagements

"$bioa [--] $BIOA not slow anymore 😅 https://t.co/psCBp4nLNF $BIOA not slow anymore 😅 https://t.co/psCBp4nLNF"
X Link 2026-01-15T15:12Z 10.1K followers, [----] engagements

"$HSAI nice break $HSAI lidar name in china https://t.co/N0q96XW6s2 $HSAI lidar name in china https://t.co/N0q96XW6s2"
X Link 2026-01-15T17:04Z 10.1K followers, [----] engagements

"$BIOA stopped remaining $bioa [--] $bioa 24"
X Link 2026-01-15T20:09Z 10.1K followers, [----] engagements

"$OLMA strong eod $OLMA https://t.co/WgGR9ABDbO $OLMA https://t.co/WgGR9ABDbO"
X Link 2026-01-15T20:59Z 10.1K followers, [----] engagements

"$FLY Morgan Stanley analyst Kristine Liwag raised the firm's price target on FireFly Aerospace to $33 from $27 and keeps an Equal Weight rating on the shares. In the Launch market of the Space Tech sector investors are watching the extent to which lift providers can commercialize new offerings and meaningfully increase cadence this year says the analyst who raised the firm's target for FireFly as the firm revisits its valuation multiple ahead of Flight 7's launch. $FLY https://t.co/1Jn7VTl78p $FLY https://t.co/1Jn7VTl78p"
X Link 2026-01-16T12:46Z 10.1K followers, [----] engagements

"$VERO crazy gap up why didn't i take cause it is former $HAIR 😅"
X Link 2026-01-16T12:57Z 10.1K followers, [----] engagements

"$LDI $LDI https://t.co/9wou3PPlYB $LDI https://t.co/9wou3PPlYB"
X Link 2026-01-16T14:56Z 10.1K followers, [----] engagements

"$BTDR $BTDR https://t.co/Zs5jeU5bWL $BTDR https://t.co/Zs5jeU5bWL"
X Link 2026-01-16T16:34Z 10.1K followers, [----] engagements

"$gmab Truist notes Genmab reported Phase [--] results from the EPCORE DLBCL-1 trial in transplant-ineligible second-line positive diffuse large B-cell lymphoma patients. The study missed its overall survival endpoint. However this outcome does not change the firm's view on the key frontline DLBCL study and Truist remains optimistic for a positive read-out this year. The firm has a Buy rating on the shares with a price target of $48. https://twitter.com/i/web/status/2012256815468191949 https://twitter.com/i/web/status/2012256815468191949"
X Link 2026-01-16T20:13Z 10.1K followers, [----] engagements

"$RIOT PTs Piper Sandler [--] Cantor [--] BTIG [--] Clear Street [--] Roth [--] Piper Sandler analyst Patrick Moley reiterated an Overweight rating and $26 price target on Riot Platforms (RIOT) after the company signed a land acquisition and data center lease with AMD (AMD) to host [--] megawatts of critical IT at Rockdale. While the initial deployment is for just [--] MW the firm thinks the deal establishes Riot as a credible data center option for hyperscaler tenants. Piper also views it as an encouraging first step towards Riot eventually contracting all roughly [---] gigawatts of critical IT across"
X Link 2026-01-16T20:20Z 10.1K followers, [----] engagements

"$INTR Inter (NASDAQ: INTR) the financial institution serving more than [--] million customers has received regulatory approval from the Florida Office of Financial Regulation (OFR) and the Federal Reserve (FED) to establish a statelicensed international banking branch in Florida marking a significant milestone in its international expansion. https://twitter.com/i/web/status/2012266861895790763 https://twitter.com/i/web/status/2012266861895790763"
X Link 2026-01-16T20:53Z 10.1K followers, [---] engagements

"$IPSC Venrock https://www.sec.gov/Archives/edgar/data/1738048/000173804826000002/xslSCHEDULE_13G_X01/primary_doc.xml $IPSC Commodore 13M 7.1% https://t.co/6UdSii2vdU https://www.sec.gov/Archives/edgar/data/1738048/000173804826000002/xslSCHEDULE_13G_X01/primary_doc.xml $IPSC Commodore 13M 7.1% https://t.co/6UdSii2vdU"
X Link 2026-01-16T21:33Z 10.1K followers, [----] engagements

"$IPSC Ra many bio funds reporting https://www.sec.gov/Archives/edgar/data/1346824/000134682426000006/xslSCHEDULE_13G_X01/primary_doc.xml $IPSC Venrock https://t.co/cPld1D0dao https://www.sec.gov/Archives/edgar/data/1346824/000134682426000006/xslSCHEDULE_13G_X01/primary_doc.xml $IPSC Venrock https://t.co/cPld1D0dao"
X Link 2026-01-16T21:37Z 10.1K followers, [----] engagements

"$FLY Goldman Sachs raised the firm's price target on FireFly Aerospace to $32 from $29 and keeps a Neutral rating on the shares. The firm's Q4 Aerospace & Defense preview highlights favorable aerospace OE conditions with supply below demand while aftermarket growth outpaces global ASMs with strong pricing supporting margins the analyst tells investors in a research note. Business jet demand remains solid amid tight supply defense hardware growth is improving though margins face risk from shifting contracts defense tech momentum emphasizes faster commercial-style providers and federal IT"
X Link 2026-01-20T12:37Z 10.1K followers, [----] engagements

"$IMRX $IMRX insider https://t.co/RmBx5DcCel $IMRX insider https://t.co/RmBx5DcCel"
X Link 2026-01-20T15:30Z 10.1K followers, [----] engagements

"$UNCY $UNCY intra high $UNCY intra high"
X Link 2026-01-20T15:36Z 10.1K followers, [----] engagements

"$ATAI decent intra trend Guggenheim initiated coverage of Atai Beckley with a Buy rating and $11 price target based on the company's position as "a differentiated leader in next-generation psychiatry." The recent merger with Beckley Psytech secures full ownership of the lead asset BPL-003 which has demonstrated "compelling" Phase IIIb efficacy and durability in treatment-resistant depression notes the analyst who believes BPL-003 is "uniquely positioned for rapid clinical adoption and commercial scale." https://twitter.com/i/web/status/2013648920920887412"
X Link 2026-01-20T16:24Z 10.1K followers, [----] engagements

"$UA $UAA decent intra vol $UAA $UA https://t.co/km5lARPFE6 $UAA $UA https://t.co/km5lARPFE6"
X Link 2026-01-20T16:31Z 10.1K followers, [----] engagements

"$TYRA decent loaders"
X Link 2026-01-20T18:06Z 10.1K followers, [----] engagements

"$MGNI decent vol follow up $MGNI https://t.co/FRMAFqVYJC $MGNI https://t.co/FRMAFqVYJC"
X Link 2026-01-20T19:47Z 10.1K followers, [----] engagements

"$DAWN nice break $DAWN https://t.co/zJru933otu $DAWN https://t.co/zJru933otu"
X Link 2026-01-20T20:12Z 10.1K followers, [----] engagements

"$PRGS Progress Software Sees Q1 Adj EPS $1.56-$1.62 vs $1.41 Est; Sees Sales $244.000M-$250.000M vs $243.565M Est / Progress Software Sees FY2026 Adj EPS $5.82-$5.96 vs $5.53 Est; Sees Sales $986.000M-$1.000B vs $978.100M Est"
X Link 2026-01-20T21:11Z 10.1K followers, [----] engagements

"$ERAS another one that should get good pricing. still holding with call exercise Erasca Inc. (Nasdaq: ERAS) a clinical-stage precision oncology company singularly focused on discovering developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers today announced that it intends to offer and sell subject to market and other conditions $150.0 million of shares of its common stock in a proposed underwritten public offering. All of the shares of common stock to be sold in the proposed offering are being offered by Erasca. In addition Erasca intends to grant the"
X Link 2026-01-20T21:19Z 10.1K followers, [----] engagements

"$PRGS $PRGS Progress Software Sees Q1 Adj EPS $1.56-$1.62 vs $1.41 Est; Sees Sales $244.000M-$250.000M vs $243.565M Est / Progress Software Sees FY2026 Adj EPS $5.82-$5.96 vs $5.53 Est; Sees Sales $986.000M-$1.000B vs $978.100M Est $PRGS Progress Software Sees Q1 Adj EPS $1.56-$1.62 vs $1.41 Est; Sees Sales $244.000M-$250.000M vs $243.565M Est / Progress Software Sees FY2026 Adj EPS $5.82-$5.96 vs $5.53 Est; Sees Sales $986.000M-$1.000B vs $978.100M Est"
X Link 2026-01-21T14:37Z 10.1K followers, [----] engagements

"$DAWN $DAWN 13s hit in AH $DAWN 13s hit in AH"
X Link 2026-01-21T14:44Z 10.1K followers, [----] engagements

"$AMKR nice bnce $AMKR https://t.co/srdHgqwaD1 $AMKR https://t.co/srdHgqwaD1"
X Link 2026-01-21T15:08Z 10.1K followers, [----] engagements

"$UA $UA $UAA decent intra vol https://t.co/yaW508238d $UA $UAA decent intra vol https://t.co/yaW508238d"
X Link 2026-01-21T16:03Z 10.1K followers, [----] engagements

"$UAL UNITED CEO - WE MADE A $500 MILLION PROFIT IN CHICAGO BUT OUR COMPETITOR LOST $500 MILLION"
X Link 2026-01-21T16:32Z 10.1K followers, [---] engagements

"$AVO 13s tdoay $AVO https://t.co/HjuThzBiaM $AVO https://t.co/HjuThzBiaM"
X Link 2026-01-21T16:36Z 10.1K followers, [----] engagements

"$UA had 2M block today $UA https://t.co/jREeqxoHLA $UA https://t.co/jREeqxoHLA"
X Link 2026-01-21T17:58Z 10.1K followers, [----] engagements

"$ALMS $ALMS Charden initiate coverage with a Buy rating PT of $37 based on the potential of its late-stage clinical pipeline in TYK2-mediated autoimmune disorders. Alumis lead asset envudeucitinib is an oral second-gen allosteric TYK2 inhibitor that recently achieved all primary $ALMS Charden initiate coverage with a Buy rating PT of $37 based on the potential of its late-stage clinical pipeline in TYK2-mediated autoimmune disorders. Alumis lead asset envudeucitinib is an oral second-gen allosteric TYK2 inhibitor that recently achieved all primary"
X Link 2026-01-21T18:56Z 10.1K followers, [----] engagements

"$UA wen [--] break $UA had 2M block today $UA had 2M block today"
X Link 2026-01-21T19:05Z 10.1K followers, [----] engagements

"$ALHC $ALHC [--] holla https://t.co/sboNiN9EOK $ALHC [--] holla https://t.co/sboNiN9EOK"
X Link 2026-01-21T19:37Z 10.1K followers, [----] engagements

"$VG On January [--] [----] the International Chamber of Commerce (ICC) International Court of Arbitration informed Venture Global Calcasieu Pass LLC (VGCP) an indirect subsidiary of Venture Global Inc. (Venture Global or the Company) that a final award had been issued in the previously disclosed arbitration proceedings with Repsol LNG Holding S.A. (Repsol) regarding LNG sales from the Calcasieu Project under the long-term LNG sales and purchase agreement entered into by VGCP and Repsol (the SPA). The award issued by the arbitration tribunal found that VGCP had acted as a Reasonable and Prudent"
X Link 2026-01-21T23:26Z 10.1K followers, [----] engagements

"$UA https://www.sec.gov/Archives/edgar/data/915191/000094787126000063/xslF345X05/ownership.xml $UA had 2M block today https://www.sec.gov/Archives/edgar/data/915191/000094787126000063/xslF345X05/ownership.xml $UA had 2M block today"
X Link 2026-01-22T01:08Z 10.1K followers, [----] engagements

"$ERAS nice pricing Erasca Inc. (Nasdaq: ERAS) a clinical-stage precision oncology company singularly focused on discovering developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers today announced the pricing of an upsized public offering of [--------] shares of its common stock. The shares of common stock are being sold to the public at a price of $10.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca . The gross proceeds to Erasca from the offering before deducting the underwriting discounts and"
X Link 2026-01-22T13:25Z 10.1K followers, [----] engagements

"$KVUE inverse pseudo scientist RFK $KVUE trimmed a few https://t.co/F4CLTqOCTI $KVUE trimmed a few https://t.co/F4CLTqOCTI"
X Link 2026-01-22T15:34Z 10K followers, [----] engagements

"$UNCY breaking $UNCY https://t.co/piSmt4aky2 $UNCY https://t.co/piSmt4aky2"
X Link 2026-01-22T15:59Z 10.1K followers, [----] engagements

"$OLMA $OLMA strong eod $OLMA strong eod"
X Link 2026-01-22T16:37Z 10.1K followers, [----] engagements

"$DAWN intact $DAWN https://t.co/QeRukg5k8I $DAWN https://t.co/QeRukg5k8I"
X Link 2026-01-22T19:04Z 10.1K followers, [----] engagements

"$FROG Feb 60c sweep"
X Link 2026-01-22T19:27Z 10.1K followers, [----] engagements

"$NKLR another one to watch in the reactor basket $NKLR former $GSRT nuclear sector rotation BRiley had $10 PT https://t.co/4nftGPELy7 $NKLR former $GSRT nuclear sector rotation BRiley had $10 PT https://t.co/4nftGPELy7"
X Link 2026-01-22T19:36Z 10.1K followers, [----] engagements

"$VG $VG https://t.co/MG4SgGFiuh $VG https://t.co/MG4SgGFiuh"
X Link 2026-01-22T20:56Z 10.1K followers, [----] engagements

"$AVR closed offering [----] $AVR https://t.co/59WAmAZeVD $AVR https://t.co/59WAmAZeVD"
X Link 2026-01-22T21:02Z 10.1K followers, [----] engagements

"$TYRA Piper Sandler raised the firm's price target on Tyra Biosciences to $42 from $33 and keeps an Overweight rating on the shares. The firm says Tyra remains a top pick for [----]. Piper believes lead asset dabogratinib is potentially best in class with application across three high-value indications driven by FGFR3 alterations namely achondroplasia IR-NMIBC and LG-UTUC. While the stock has outperformed recently the firm sees significant upside remaining as the company approaches key de-risking clinical catalysts in IR-NMIBC and achondroplasia. $TYRA decent loaders https://t.co/okOPRHA2VC"
X Link 2026-01-23T12:53Z 10.1K followers, [----] engagements

"$UA $UAA a bit conservative PT Citi analyst Paul Lejuez raised the firm's price target on Under Armour to $6.50 from $5 and keeps a Neutral rating on the shares. $UA https://t.co/XPSJMLMiSx https://t.co/Ik33I3SBWb $UA https://t.co/XPSJMLMiSx https://t.co/Ik33I3SBWb"
X Link 2026-01-23T12:54Z 10.1K followers, [----] engagements

"$RZLT $RZLT https://t.co/QEGPjgh6g5 $RZLT https://t.co/QEGPjgh6g5"
X Link 2026-01-23T15:35Z 10.1K followers, [----] engagements

"$FROG $FROG Feb 60c sweep $FROG Feb 60c sweep"
X Link 2026-01-23T16:20Z 10.1K followers, [----] engagements

"$LDI intraday block today $LDI https://t.co/OEJ3mOdwrZ $LDI https://t.co/OEJ3mOdwrZ"
X Link 2026-01-23T19:33Z 10.1K followers, [----] engagements

"$ERAS Erasca Announces Closing of Upsized Public Offering of Common Stock Including Full Exercise of Underwriters Option to Purchase Additional Shares $ERAS nice pricing Erasca Inc. (Nasdaq: ERAS) a clinical-stage precision oncology company singularly focused on discovering developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers today announced the pricing of an upsized public offering $ERAS nice pricing Erasca Inc. (Nasdaq: ERAS) a clinical-stage precision oncology company singularly focused on discovering developing and commercializing therapies for"
X Link 2026-01-23T21:02Z 10.1K followers, [----] engagements

"$IOBT Novo Holdings decreased stake to 2.47M 3.3% from 4.98M 7.3% Piper Sandler downgraded to [---] from 3"
X Link 2026-01-24T00:16Z 10.1K followers, [---] engagements

"$ERAS Morgan Stanley analyst Sean Laaman raised the firm's price target on Erasca to $10 from $4 and keeps an Equal Weight rating on the shares after the company shared an early clinical look at ERAS-0015 and reported two confirmed partial responses and one unconfirmed PR at [--] mg QD. While these data are "promising" and the firm raised its view of the odds of success as a result it acknowledges "it remains early." $ERAS Erasca Announces Closing of Upsized Public Offering of Common Stock Including Full Exercise of Underwriters Option to Purchase Additional Shares $ERAS Erasca Announces Closing"
X Link 2026-01-26T13:21Z 10.1K followers, [----] engagements

"$AB $AB https://t.co/YoVMnyYjEM $AB https://t.co/YoVMnyYjEM"
X Link 2026-01-26T16:50Z 10.1K followers, [----] engagements

"$ALMS decent bnce $ALMS [--] got avged up with call exercise https://t.co/jrf8igHNz3 $ALMS [--] got avged up with call exercise https://t.co/jrf8igHNz3"
X Link 2026-01-26T16:56Z 10.1K followers, [----] engagements

"$TEVA nice intra block $TEVA Truist raised the firm's price target on Teva to $36 from $32 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into [----] the analyst tells investors in a research note. $TEVA Truist raised the firm's price target on Teva to $36 from $32 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into [----] the analyst tells investors in a research note"
X Link 2026-01-26T17:29Z 10.1K followers, [----] engagements

"$TARA lazy river today $TARA On track to report interim results from approximately [--] six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 [----] Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H [----] Dosed first patient $TARA On track to report interim results from approximately [--] six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 [----] Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H [----] Dosed first patient"
X Link 2026-01-26T17:53Z 10.1K followers, [----] engagements

"$AB $AB https://t.co/e7bVWzrfWL $AB https://t.co/e7bVWzrfWL"
X Link 2026-01-26T19:39Z 10.1K followers, [----] engagements

"$DTCX former $TZUP notable bnce"
X Link 2026-01-26T19:44Z 10.1K followers, [---] engagements

"$AB near [--] $AB https://t.co/yCO196Vw4k $AB https://t.co/yCO196Vw4k"
X Link 2026-01-26T20:03Z 10.1K followers, [----] engagements

"$AB 40c $AB near [--] $AB near 42"
X Link 2026-01-26T20:23Z 10.1K followers, [----] engagements

"$ALMS nice into close $ALMS decent bnce https://t.co/8UD8W5ZfFE $ALMS decent bnce https://t.co/8UD8W5ZfFE"
X Link 2026-01-26T20:51Z 10.1K followers, [----] engagements

"$LUNR The National Aeronautics and Space Administration has announced its selection of Intuitive Machines as part of [--] global volunteers chosen to track the Artemis II Mission the company announced. "The company will support the mission using its Space Data Network and ground station infrastructure. Intuitive Machines is among volunteers spanning commercial service providers members of academia and individual amateur radio enthusiasts approved by NASA to track the radio waves transmitted by the Orion spacecraft during its 10-day journey to and around the Moon. The mission's first launch"
X Link 2026-01-26T21:10Z 10.1K followers, [----] engagements

"$CAPR Tang 3.4M 6.6% https://www.sec.gov/Archives/edgar/data/1133869/000121465926000831/xslSCHEDULE_13G_X01/primary_doc.xml https://www.sec.gov/Archives/edgar/data/1133869/000121465926000831/xslSCHEDULE_13G_X01/primary_doc.xml"
X Link 2026-01-26T21:16Z 10.1K followers, [----] engagements

"$UA $UAA $UAA https://t.co/Dt3kiSRSap $UAA https://t.co/Dt3kiSRSap"
X Link 2026-01-26T23:52Z 10.1K followers, [----] engagements

"$BIOA Piper Sandler initiated coverage of BioAge Labs with an Overweight rating and $73 price target. The company's BGE-102 is an oral QD CNS-penetrant NLRP3 inhibitor small-molecule with "strong" Phase [--] data in obese patients the analyst tells investors in a research note. Piper views BioAge as a "key name to own." https://twitter.com/i/web/status/2016121706662822106 https://twitter.com/i/web/status/2016121706662822106"
X Link 2026-01-27T12:10Z 10.1K followers, [----] engagements

"$DVN Wells Fargo raised the firm's price target on Devon Energy to $43 from $37 and keeps an Overweight rating on the shares. The oil macro remains pressured with downside-skewed fundamentals as rising OPEC supply and strong non-OPEC growth point to a near-term surplus and continued price pressure Wells notes. Amid a softer macro the firm favors low-reinvestment capital-disciplined frameworks with [----] plans broadly stable across the group. $DVN $CTRA US shale producers Devon Energy and Coterra Energy in merger talks sources say $DVN $CTRA US shale producers Devon Energy and Coterra Energy in"
X Link 2026-01-27T12:30Z 10.1K followers, [----] engagements

"$ERAS Guggenheim [--] from [--] Mizuho [--] Mizuho analyst Joseph Catanzaro assumed coverage of Erasca with an Outperform rating and price target of $16 up from $5. The firm says the company's RAS inhibitor portfolio is well positioned to establish proof-of-concept in [----]. ERAS-0015 has opportunity for a wider therapeutic window and a competitive clinical profile the analyst tells investors in a research note. $ERAS Morgan Stanley analyst Sean Laaman raised the firm's price target on Erasca to $10 from $4 and keeps an Equal Weight rating on the shares after the company shared an early clinical look"
X Link 2026-01-27T13:47Z 10.1K followers, [----] engagements

"$ALMS nearing [--] $ALMS nice into close $ALMS nice into close"
X Link 2026-01-27T15:25Z 10.1K followers, [----] engagements

"$GDS $GDS weekly https://t.co/JMXNwjCstk $GDS weekly https://t.co/JMXNwjCstk"
X Link 2026-01-27T15:36Z 10.1K followers, [----] engagements

"$BILI $BILI pcr .103 today $BILI pcr .103 today"
X Link 2026-01-27T15:41Z 10.1K followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing